Cleo Diagnostics (COV) Short Interest
Cleo Diagnostics (ASX:COV) had 0.00% of shares reported as short positions as of 24 Aug 2026, representing 6,300 shares. Cleo Diagnostics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Cleo Diagnostics
Cleo Diagnostics is a medical diagnostics company focused on developing and commercializing novel cancer diagnostic solutions, particularly for ovarian cancer. Their focus is on creating accessible and accurate diagnostic tests. The company aims to improve early detection and treatment outcomes for women's health.
Short position
Cleo Diagnostics (ASX:COV) has 0.00% of its shares on issue reported as short positions as of 24 Aug 2026, or about 6,300 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. COV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4COV intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Cleo Diagnostics
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss COV
Start a research thread or post the first pulse update